首页 > 最新文献

Doklady Biochemistry and Biophysics最新文献

英文 中文
Course of Uveitis in Patients with Ankylosing Spondylitis during the Interleukin17 Inhibitors Therapy 强直性脊柱炎患者在白细胞介素17抑制剂治疗期间的葡萄膜炎病程
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-06-10 DOI: 10.1134/S1607672924700868
A. A. Godzenko, E. M. Agafonova, A. E. Dimitreva, I. Yu. Razumova, M. M. Urumova

Biological disease-modifying antirheumatic drugs (bDMARDs) can have different effects on various clinical manifestations of ankylosing spondylitis (AS). Data on the effects of interleukin 17 inhibitors (IL17-i) on uveitis in AS continue to accumulate. Objective: to evaluate the effect of IL17-i therapy on the course of uveitis in AS. The study involved 73 patients with AS (New York criteria, 1984), who received IL17-i (57—secukinumab (SEC), 22—netakimab (NTK)) for at least 1 year. The average age of patients at the time of inclusion in the study was 41.93 ± 8.95 years, the average duration of AS was 10.75 ± 6.22 years. There were 40 men (56.7%) and 33 women (43.3%) among the patients. HLA-B27 was detected in 62/73 (85%), coxitis in 58 (79%), enthesitis in 63 (86.3%), peripheral arthritis in 57 (78%), psoriasis in 7 (9.5%), and inflammatory bowel disease (IBD) in 3 (4.1%) patients; in 6 (8.2%) patients, the disease started before the age of 16; 19 (26%) patients had at least one episode of uveitis during the course of the disease. The rates of uveitis was estimated by comparing the number of incidences per 100 patient-years before the start of bDMARDs therapy and during IL17-i using. The incidence rate of uveitis before the start of bDMARDs therapy for all patients was 8.3 per 100 pt-years (95% CI 0.065–0.107), during IL17-i therapy— 9.2 per 100 pt-years (95% CI 0.06–0.15), p = 0.72. The incidence rate of uveitis among patients who used SEC was 10.1 per 100 pt-years (95% CI 0.079–0.13) before the start of bDMARDs therapy and 9.4 per 100 pt-years (95% CI 0.05-0.15), p = 0.74 during SEC therapy. The incidence rate of uveitis among patients who used NTK was 4.8 per 100 pt-years (95% CI 0.028–0.08) before the start of bDMARDs therapy and 7.1 per 100 pt-years (95% CI 0.019–022), p = 0.3 during the NTK therapy. For patients with a history of uveitis, the incidence rate of uveitis was 22.5 per 100 pt-years (95% CI 0.18–0.28) before the start of therapy with bDMARDs and 29.1 per 100 pt-years (95% CI 0.18–0.43), p = 0.29 during IL17-i therapy. Occurrences of uveitis were observed in 4 of 57 patients (7%) during SEC therapy and in 1 of 25 (4%) patients during the NTK therapy. One case of new-onset uveitis was recorded during the using of SEC. There were no significant differences in the incidence rates of uveitis during IL17-i therapy compared with non-biological therapy. IL17-i therapy have not demonstrated a significant effect on the course of uveitis in AS in the study group.

生物改良抗风湿药(bDMARDs)对强直性脊柱炎(AS)的各种临床表现有不同的影响。有关白细胞介素17抑制剂(IL17-i)对强直性脊柱炎葡萄膜炎影响的数据仍在不断积累。目的:评估IL17-i疗法对强直性脊柱炎葡萄膜炎病程的影响。研究涉及73名强直性脊柱炎患者(纽约标准,1984年),他们接受IL17-i(57-secukinumab (SEC),22-netakimab (NTK))治疗至少1年。患者纳入研究时的平均年龄为(41.93±8.95)岁,强直性脊柱炎的平均病程为(10.75±6.22)年。患者中有 40 名男性(56.7%)和 33 名女性(43.3%)。62/73(85%)例患者检测到 HLA-B27,58(79%)例患者患有髋关节炎,63(86.3%)例患者患有腱鞘炎,57(78%)例患者患有外周关节炎,7(9.5%)例患者患有银屑病,3(4.1%)例患者患有炎症性肠病(IBD);6(8.2%)例患者在 16 岁前开始患病;19(26%)例患者在患病期间至少发作过一次葡萄膜炎。葡萄膜炎的发病率是通过比较开始使用 bDMARDs 治疗前和使用 IL17-i 期间每 100 患者年的发病次数估算得出的。在开始使用bDMARDs治疗前,所有患者的葡萄膜炎发病率为每100 pt-年8.3例(95% CI 0.065-0.107),在使用IL17-i治疗期间为每100 pt-年9.2例(95% CI 0.06-0.15),P = 0.72。在开始使用bDMARDs治疗前,使用SEC的患者葡萄膜炎发病率为每100 pt-年10.1例(95% CI 0.079-0.13),在SEC治疗期间为每100 pt-年9.4例(95% CI 0.05-0.15),P = 0.74。使用NTK的患者葡萄膜炎发病率在开始使用bDMARDs治疗前为每100 pt-年4.8例(95% CI 0.028-0.08),在NTK治疗期间为每100 pt-年7.1例(95% CI 0.019-022),p = 0.3。对于有葡萄膜炎病史的患者,在开始使用bDMARDs治疗前,葡萄膜炎的发生率为每100 pt-年22.5例(95% CI 0.18-0.28),在IL17-i治疗期间,葡萄膜炎的发生率为每100 pt-年29.1例(95% CI 0.18-0.43),p = 0.29。在 SEC 治疗期间,57 例患者中有 4 例(7%)出现葡萄膜炎;在 NTK 治疗期间,25 例患者中有 1 例(4%)出现葡萄膜炎。在使用 SEC 治疗期间,记录到一例新发葡萄膜炎。与非生物疗法相比,IL17-i疗法的葡萄膜炎发病率没有明显差异。在研究组中,IL17-i疗法对强直性脊柱炎葡萄膜炎的病程没有明显影响。
{"title":"Course of Uveitis in Patients with Ankylosing Spondylitis during the Interleukin17 Inhibitors Therapy","authors":"A. A. Godzenko,&nbsp;E. M. Agafonova,&nbsp;A. E. Dimitreva,&nbsp;I. Yu. Razumova,&nbsp;M. M. Urumova","doi":"10.1134/S1607672924700868","DOIUrl":"10.1134/S1607672924700868","url":null,"abstract":"<p>Biological disease-modifying antirheumatic drugs (bDMARDs) can have different effects on various clinical manifestations of ankylosing spondylitis (AS). Data on the effects of interleukin 17 inhibitors (IL17-i) on uveitis in AS continue to accumulate. Objective: to evaluate the effect of IL17-i therapy on the course of uveitis in AS. The study involved 73 patients with AS (New York criteria, 1984), who received IL17-i (57—secukinumab (SEC), 22—netakimab (NTK)) for at least 1 year. The average age of patients at the time of inclusion in the study was 41.93 ± 8.95 years, the average duration of AS was 10.75 ± 6.22 years. There were 40 men (56.7%) and 33 women (43.3%) among the patients. HLA-B27 was detected in 62/73 (85%), coxitis in 58 (79%), enthesitis in 63 (86.3%), peripheral arthritis in 57 (78%), psoriasis in 7 (9.5%), and inflammatory bowel disease (IBD) in 3 (4.1%) patients; in 6 (8.2%) patients, the disease started before the age of 16; 19 (26%) patients had at least one episode of uveitis during the course of the disease. The rates of uveitis was estimated by comparing the number of incidences per 100 patient-years before the start of bDMARDs therapy and during IL17-i using. The incidence rate of uveitis before the start of bDMARDs therapy for all patients was 8.3 per 100 pt-years (95% CI 0.065–0.107), during IL17-i therapy— 9.2 per 100 pt-years (95% CI 0.06–0.15), <i>p</i> = 0.72. The incidence rate of uveitis among patients who used SEC was 10.1 per 100 pt-years (95% CI 0.079–0.13) before the start of bDMARDs therapy and 9.4 per 100 pt-years (95% CI 0.05-0.15), <i>p</i> = 0.74 during SEC therapy. The incidence rate of uveitis among patients who used NTK was 4.8 per 100 pt-years (95% CI 0.028–0.08) before the start of bDMARDs therapy and 7.1 per 100 pt-years (95% CI 0.019–022), <i>p</i> = 0.3 during the NTK therapy. For patients with a history of uveitis, the incidence rate of uveitis was 22.5 per 100 pt-years (95% CI 0.18–0.28) before the start of therapy with bDMARDs and 29.1 per 100 pt-years (95% CI 0.18–0.43), <i>p</i> = 0.29 during IL17-i therapy. Occurrences of uveitis were observed in 4 of 57 patients (7%) during SEC therapy and in 1 of 25 (4%) patients during the NTK therapy. One case of new-onset uveitis was recorded during the using of SEC. There were no significant differences in the incidence rates of uveitis during IL17-i therapy compared with non-biological therapy. IL17-i therapy have not demonstrated a significant effect on the course of uveitis in AS in the study group.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"517 1","pages":"166 - 172"},"PeriodicalIF":0.8,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the Possibility of Axial Psoriatic Arthritis Patients Meeting Classification Criteria for Axial Spondyloarthritis and Ankylosing Spondylitis 评估轴性银屑病关节炎患者符合轴性脊柱关节炎和强直性脊柱炎分类标准的可能性。
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-06-10 DOI: 10.1134/S160767292470087X
E. E. Gubar, T. V. Korotaeva, Yu. L. Korsakova, E. Yu. Loginova, A. V. Smirnov, A. V. Sukhinina, M. M. Urumova, S. I. Glukhova

The objective of the study was to analyze whether axial psoriatic arthritis (axPsA) patients meet classification criteria for axial spondyloarthritis (axSpA) and ankylosing spondylitis (AS). A total of 104 patients (66 men and 38 women) with PsA according to CASPAR criteria were examined, all patients had back pain. Patients were evaluated for presence of inflammatory back pain (IBP) by ASAS criteria. Back pain not meeting the ASAS criteria was taken to be chronic back pain (chrBP). Patients underwent hands, feet and pelvis, cervical spine and lumbar spine X-rays. Erosions, osteolysis, and juxta-articular new bone formation were evaluated. Definite radiographic sacroiliitis (d-rSI) was defined as bilateral grade ≥ 2 or unilateral grade ≥ 3. Nineteen patients without d-rSI underwent sacroiliac joints MRI. Ninety-three patients underwent HLA B27 examination. The number of patients who met the criteria for axSpA (ASAS) and the modified New York (mNY) criteria for AS was determined. IBP was identified in 67 (64.4%) patients; chrBP, in 37 (35.6%) patients; 31 (29.8%) patient were of older age (over 40) at the onset of IBP/chrBP; 57 (58.8%) patients had d-rSI; 6 (31.6%) patients had MRI-SI; syndesmophytes were detected in 57 (58.8%) cases. Among 40 patients without d-rSI, 19 (47.5%) had syndesmophytes. In 38/97 (39.2%) patients d-rSI was detected along with syndesmophytes, while 19/97 (19.6%) patients had isolated d-rSI without spondylitis, and 19/97 (19.6%) patients had isolated syndesmophytes without d-rSI. HLA B27 was present in 28 (30.1%) cases. 51 (55.4%) patients met criteria for axSpA. Forty-one (44.6%) patients did not meet criteria for axSpA; however, 27 (65.9%) of them had syndesmophytes. Forty-eight (48.5%) PsA patients met mNY criteria for AS. Among these patients, a set of specific features was revealed: 18 (37.5%) had no IBP, 18 (37.5%) were of older age (over 40) at the onset of IBP/chrBP, 34 (70.8%) had dactylitis, 38 (79.2%) had erosive polyarthritis, 23 (48.8%) had juxta-articular new bone formation, 14 (30.2%) had osteolysis, 23 (48.9%) had “chunky” non-marginal syndesmophytes, and 40 (82.6%) had nail psoriasis; 28 (66.6%) patients were HLA-B27 negative. Forty-five percent of axPsA patients do not meet criteria for axSpA. Characteristic features have been identified to differentiate axPsA from AS.

该研究旨在分析轴性银屑病关节炎(axPsA)患者是否符合轴性脊柱关节炎(axSpA)和强直性脊柱炎(AS)的分类标准。根据 CASPAR 标准,共对 104 名 PsA 患者(66 名男性和 38 名女性)进行了检查,所有患者都有背痛。根据 ASAS 标准评估了患者是否存在炎性背痛(IBP)。不符合 ASAS 标准的背痛被视为慢性背痛(chrBP)。患者接受手、脚、骨盆、颈椎和腰椎 X 光检查。对侵蚀、骨溶解和并关节新骨形成进行了评估。双侧骶髂关节炎≥2级或单侧骶髂关节炎≥3级即为明确的放射性骶髂关节炎(d-rSI)。19名无d-rSI的患者接受了骶髂关节磁共振成像检查。93 名患者接受了 HLA B27 检查。符合axSpA(ASAS)标准和改良纽约(mNY)AS标准的患者人数已确定。67例(64.4%)患者被确定为IBP;37例(35.6%)患者被确定为chrBP;31例(29.8%)患者在IBP/chrBP发病时年龄较大(超过40岁);57例(58.8%)患者有d-rSI;6例(31.6%)患者有MRI-SI;57例(58.8%)患者被检测出联合骨赘。在 40 位未患有 d-rSI 的患者中,19 位(47.5%)患有联合叶状体。在 38/97 (39.2%) 例患者中,d-rSI 与联合叶状体同时被检测到,19/97 (19.6%) 例患者有孤立的 d-rSI 而无脊柱炎,19/97 (19.6%) 例患者有孤立的联合叶状体而无 d-rSI。28例(30.1%)患者存在 HLA B27。51例(55.4%)患者符合axSpA的标准。41例(44.6%)患者不符合axSpA的标准,但其中27例(65.9%)有联合叶状体。48名(48.5%)PsA患者符合mNY AS标准。在这些患者中,发现了一系列特殊的特征:18人(37.5%)没有IBP,18人(37.5%)在IBP/chrBP发病时年龄较大(超过40岁),34人(70.8%)患有趾间关节炎,38人(79.2%)患有侵蚀性多关节炎,23人(48.28(66.6%)名患者的 HLA-B27 阴性。45%的 axPsA 患者不符合 axSpA 的标准。目前已确定了可将 axPsA 与 AS 区分开来的特征。
{"title":"Evaluation of the Possibility of Axial Psoriatic Arthritis Patients Meeting Classification Criteria for Axial Spondyloarthritis and Ankylosing Spondylitis","authors":"E. E. Gubar,&nbsp;T. V. Korotaeva,&nbsp;Yu. L. Korsakova,&nbsp;E. Yu. Loginova,&nbsp;A. V. Smirnov,&nbsp;A. V. Sukhinina,&nbsp;M. M. Urumova,&nbsp;S. I. Glukhova","doi":"10.1134/S160767292470087X","DOIUrl":"10.1134/S160767292470087X","url":null,"abstract":"<p>The objective of the study was to analyze whether axial psoriatic arthritis (axPsA) patients meet classification criteria for axial spondyloarthritis <b>(</b>axSpA) and ankylosing spondylitis (AS). A total of 104 patients (66 men and 38 women) with PsA according to CASPAR criteria were examined, all patients had back pain. Patients were evaluated for presence of inflammatory back pain (IBP) by ASAS criteria. Back pain not meeting the ASAS criteria was taken to be chronic back pain (chrBP). Patients underwent hands, feet and pelvis, cervical spine and lumbar spine X-rays. Erosions, osteolysis, and juxta-articular new bone formation were evaluated. Definite radiographic sacroiliitis (d-rSI) was defined as bilateral grade ≥ 2 or unilateral grade ≥ 3. Nineteen patients without d-rSI underwent sacroiliac joints MRI. Ninety-three patients underwent HLA B27 examination. The number of patients who met the criteria for axSpA (ASAS) and the modified New York (mNY) criteria for AS was determined. IBP was identified in 67 (64.4%) patients; chrBP, in 37 (35.6%) patients; 31 (29.8%) patient were of older age (over 40) at the onset of IBP/chrBP; 57 (58.8%) patients had d-rSI; 6 (31.6%) patients had MRI-SI; syndesmophytes were detected in 57 (58.8%) cases. Among 40 patients without d-rSI, 19 (47.5%) had syndesmophytes. In 38/97 (39.2%) patients d-rSI was detected along with syndesmophytes, while 19/97 (19.6%) patients had isolated d-rSI without spondylitis, and 19/97 (19.6%) patients had isolated syndesmophytes without d-rSI. HLA B27 was present in 28 (30.1%) cases. 51 (55.4%) patients met criteria for axSpA. Forty-one (44.6%) patients did not meet criteria for axSpA; however, 27 (65.9%) of them had syndesmophytes. Forty-eight (48.5%) PsA patients met mNY criteria for AS. Among these patients, a set of specific features was revealed: 18 (37.5%) had no IBP, 18 (37.5%) were of older age (over 40) at the onset of IBP/chrBP, 34 (70.8%) had dactylitis, 38 (79.2%) had erosive polyarthritis, 23 (48.8%) had juxta-articular new bone formation, 14 (30.2%) had osteolysis<b>,</b> 23 (48.9%) had “chunky” non-marginal syndesmophytes, and 40 (82.6%) had nail psoriasis; 28 (66.6%) patients were HLA-B27 negative. Forty-five percent of axPsA patients do not meet criteria for axSpA. Characteristic features have been identified to differentiate axPsA from AS.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"517 1","pages":"173 - 181"},"PeriodicalIF":0.8,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and Tolerability of Rituximab in the Treatment of Systemic Sclerosis 利妥昔单抗治疗系统性硬化症的安全性和耐受性
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-06-10 DOI: 10.1134/S1607672924700856
L. A. Garzanova, L. P. Ananyeva, O. A. Koneva, O. V. Desinova, M. N. Starovoytova, O. B. Ovsyannikova, R. U. Shayakhmetova, S. I. Glukhova

Rituximab (RTX) has been used for the treatment of systemic sclerosis (SSс) for a long time and has shown good efficacy for skin fibrosis and interstitial lung disease (ILD). However, data on tolerability and long-term adverse events (AEs) during RTX therapy in SSc are insufficient. The objective of this study was to assess the tolerability and safety of RTX in patients with SSс in a long-term prospective follow-up. Our open-label prospective study included 151 SSс patients who received at least one RTX infusion. The mean age of the patients was 47.9 ± 13.4 years; the majority of them were women (83%). The mean disease duration was 6.4 ± 5.8 years. The mean follow-up period after the first RTX infusion was 5.6 ± 2.6 years (845.6 patient-years (PY)). All patients received RTX in addition to ongoing therapy with prednisone and/or immunosuppressants. AEs were assessed and recorded by a doctor in the hospital immediately after RTX infusion and then by patient’s reported outcome during the observation period. All causes of death were considered, regardless of treatment. A total of 85 AEs (56%) were registered, the overall incidence of AEs was 10/100 PY (95% confidence interval (CI) 8–12). The highest frequency of all AEs was observed in the first 2–6 months after the first course of RTX, however, these were mainly mild and moderate AEs (71%). The most frequent AEs were infections, they were observed in 40% of cases, with no serious opportunistic infections reported. The overall incidence of all infections was 7.1/100 PY (95% CI 5.5–9), serious infections—1.5/100 PY (95% CI 0.9–2.6). Infusion reactions occurred in 8% of patients. Other AEs were noted in 3% (0.6/100 PY, 95% CI 0.3–1.4). The overall incidence of serious AEs was 18%—3.2/100 PY (95% CI 2.2–4.6). There was a significant decrease of the immunoglobulin G (Ig G) during follow-up; however, its average values remained within normal limits. There were 17 deaths (11%) (2/100 PY, 95% CI 1.3–3.2). In most cases, patients died from the progression of the major organ failure, which arose before RTX treatment. In our study, the safety profile of RTX in SSс was assessed as favorable. It was similar to the AE profile in other autoimmune diseases treated with RTX. With an increase in the cumulative dose of RTX, no increase in AEs was observed. The mortality is comparable to the other severe autoimmune diseases in observational studies. Monitoring of IgG may be useful for patients with SSс on RTX therapy for early detection of the risk of developing infectious complications. RTX could be considered as a relatively safe drug for the complex therapy of SSс when standard therapy is ineffective or impossible.

利妥昔单抗(RTX)用于治疗系统性硬化症(SSс)已有很长一段时间,对皮肤纤维化和间质性肺病(ILD)显示出良好的疗效。然而,有关RTX治疗系统性硬化症期间的耐受性和长期不良事件(AEs)的数据尚不充分。本研究旨在通过长期前瞻性随访评估RTX在SSс患者中的耐受性和安全性。我们的开放标签前瞻性研究纳入了151名至少接受过一次RTX输注的SSс患者。患者的平均年龄为(47.9 ± 13.4)岁,其中大多数为女性(83%)。平均病程为(6.4 ± 5.8)年。首次输注 RTX 后的平均随访时间为 5.6 ± 2.6 年(845.6 患者年)。所有患者在接受泼尼松和/或免疫抑制剂治疗的同时还接受了RTX治疗。在输注 RTX 后,由医院的一名医生立即对 AEs 进行评估和记录,然后根据患者在观察期间报告的结果进行评估和记录。所有死亡原因均被考虑在内,与治疗无关。共登记了 85 例 AEs(56%),AEs 的总发生率为 10/100 PY(95% 置信区间 (CI):8-12)。在首个 RTX 疗程后的 2-6 个月内,所有 AE 的发生率最高,但主要是轻度和中度 AE(71%)。最常见的不良反应是感染,占 40%,没有严重机会性感染的报道。所有感染的总发生率为 7.1/100PY(95% CI 5.5-9),严重感染为 1.5/100PY(95% CI 0.9-2.6)。8%的患者发生了输液反应。其他 AE 为 3%(0.6/100 人,95% CI 0.3-1.4)。严重 AEs 的总发生率为 18%-3.2/100PY(95% CI 2.2-4.6)。随访期间,免疫球蛋白 G(Ig G)明显下降,但其平均值仍在正常范围内。共有 17 人死亡(11%)(2/100 PY,95% CI 1.3-3.2)。在大多数病例中,患者死于 RTX 治疗前出现的主要器官功能衰竭。在我们的研究中,RTX治疗SSс的安全性评价良好。它与其他接受RTX治疗的自身免疫性疾病的AE情况相似。随着RTX累积剂量的增加,未观察到AEs增加。死亡率与观察性研究中的其他严重自身免疫性疾病相当。对接受RTX治疗的SSс患者进行IgG监测可能有助于及早发现发生感染性并发症的风险。当标准疗法无效或无法使用时,RTX可被视为一种相对安全的药物,用于SSс的综合治疗。
{"title":"Safety and Tolerability of Rituximab in the Treatment of Systemic Sclerosis","authors":"L. A. Garzanova,&nbsp;L. P. Ananyeva,&nbsp;O. A. Koneva,&nbsp;O. V. Desinova,&nbsp;M. N. Starovoytova,&nbsp;O. B. Ovsyannikova,&nbsp;R. U. Shayakhmetova,&nbsp;S. I. Glukhova","doi":"10.1134/S1607672924700856","DOIUrl":"10.1134/S1607672924700856","url":null,"abstract":"<p>Rituximab (RTX) has been used for the treatment of systemic sclerosis (SSс) for a long time and has shown good efficacy for skin fibrosis and interstitial lung disease (ILD). However, data on tolerability and long-term adverse events (AEs) during RTX therapy in SSc are insufficient. The objective of this study was to assess the tolerability and safety of RTX in patients with SSс in a long-term prospective follow-up. Our open-label prospective study included 151 SSс patients who received at least one RTX infusion. The mean age of the patients was 47.9 ± 13.4 years; the majority of them were women (83%). The mean disease duration was 6.4 ± 5.8 years. The mean follow-up period after the first RTX infusion was 5.6 ± 2.6 years (845.6 patient-years (PY)). All patients received RTX in addition to ongoing therapy with prednisone and/or immunosuppressants. AEs were assessed and recorded by a doctor in the hospital immediately after RTX infusion and then by patient’s reported outcome during the observation period. All causes of death were considered, regardless of treatment. A total of 85 AEs (56%) were registered, the overall incidence of AEs was 10/100 PY (95% confidence interval (CI) 8–12). The highest frequency of all AEs was observed in the first 2–6 months after the first course of RTX, however, these were mainly mild and moderate AEs (71%). The most frequent AEs were infections, they were observed in 40% of cases, with no serious opportunistic infections reported. The overall incidence of all infections was 7.1/100 PY (95% CI 5.5–9), serious infections—1.5/100 PY (95% CI 0.9–2.6). Infusion reactions occurred in 8% of patients. Other AEs were noted in 3% (0.6/100 PY, 95% CI 0.3–1.4). The overall incidence of serious AEs was 18%—3.2/100 PY (95% CI 2.2–4.6). There was a significant decrease of the immunoglobulin G (Ig G) during follow-up; however, its average values remained within normal limits. There were 17 deaths (11%) (2/100 PY, 95% CI 1.3–3.2). In most cases, patients died from the progression of the major organ failure, which arose before RTX treatment. In our study, the safety profile of RTX in SSс was assessed as favorable. It was similar to the AE profile in other autoimmune diseases treated with RTX. With an increase in the cumulative dose of RTX, no increase in AEs was observed. The mortality is comparable to the other severe autoimmune diseases in observational studies. Monitoring of IgG may be useful for patients with SSс on RTX therapy for early detection of the risk of developing infectious complications. RTX could be considered as a relatively safe drug for the complex therapy of SSс when standard therapy is ineffective or impossible.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"517 1","pages":"156 - 165"},"PeriodicalIF":0.8,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diastolic Dysfunction of the Left and Right Ventricles in Patients with Calcium Pyrophosphate Crystal Storage Disease and Osteoarthritis 焦磷酸钙晶体贮积症和骨关节炎患者左右心室的舒张功能障碍
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-06-10 DOI: 10.1134/S1607672924700881
M. S. Eliseev, O. V. Zhelyabina, I. G. Kirillova, Yu. O. Korsakova, E. V. Cheremushkina

The frequency and risk factors for the development of diastolic dysfunction (DD) in patients with CPPD and OA have not been studied. The objective of this study was to determine the frequency and identify risk factors (RF) for the development of DD of the left and right ventricles (LV and RV) in patients with calcium pyrophosphate crystal deposition disease (CPPD) and osteoarthritis (OA). The study included 26 patients with CPPD and with knee OA 18–65 years old, matched in age and gender, without cardiovascular disease (CVD), type 2 diabetes mellitus (DM2), and rheumatic diseases. Conventional risk factors (TRF) of CVD were assessed, and echocardiography was performed. The frequency of DD in patients with CPPD and OA was quite high and almost did not differ in both groups: it was detected in 19 patients, of which 11 (42%) had CPPD and 8 (31%) had OA (p = 0.39). Type 1 LV DD was detected in 10 (39%) patients with CPPD and in 8 (31%) with OA (p = 0.11); type 1RV DD was detected in 8 (31%) patients with CPPD and in 7 (27%) patients with OA (p = 0.17); and type 1 LV DD and RV DD was detected in 7 (27%) patients with both CPPD and with OA. DD types 2 and 3 were not detected in both groups. There were no differences in both groups in CV risk factors, except for the level of CRP (it was higher in CPPD) (p = 0.03). In the CPPD group, mean values of LV E/E' (p = 0.02), LVDT (p = 0.03), LVMI (p = 0.04) were significantly higher than in patients with OA. On the contrary, in patients with OA, indices EDV (p = 0.004) and TVC (p = 0.02) were higher. There were direct correlations between diastolic function indices and the following factors in CPPD: LVL, PWLV and PTH level (r = 0.7, p <0.005), LV E' and PTH level (r = 0.7, p < 0.005). Inverse correlations were found between the level of PTH and IS (r = –0.5, p < 0.005), LVMI (r = –0.5, p < 0.005), and the level of vitamin D and VDDT (r = –0.6, p < 0.005). Direct correlations in OA were found between the level of CRP and PVAdiast (r = 0.6, p < 0.005), and the level of sUA (r = 0.7, p < 0.005), and the level of vitamin D and E/E'LV (r = 0.6, p < 0.005). A high prevalence of LV and RV DD was found in patients with CPPD and OA. The presence of DD in CPPD was associated with lower vitamin D levels, and in OA with a higher level of sUA and a lower level of PTH.

关于焦磷酸钙晶体沉积症和OA患者发生舒张功能障碍(DD)的频率和风险因素尚未进行研究。本研究旨在确定焦磷酸钙晶体沉积症(CPPD)和骨关节炎(OA)患者左心室和右心室(LV和RV)舒张功能障碍(DD)发生的频率并识别其风险因素(RF)。该研究纳入了26名年龄在18-65岁之间的焦磷酸钙晶体沉积症和膝关节OA患者,他们的年龄和性别匹配,无心血管疾病(CVD)、2型糖尿病(DM2)和风湿病。对心血管疾病的常规危险因素(TRF)进行了评估,并进行了超声心动图检查。CPPD和OA患者出现DD的频率相当高,而且两组患者几乎没有差异:19名患者中发现了DD,其中11人(42%)患有CPPD,8人(31%)患有OA(P = 0.39)。10 名(39%)CPPD 患者和 8 名(31%)OA 患者检测到 1 型 LV DD(p = 0.11);8 名(31%)CPPD 患者和 7 名(27%)OA 患者检测到 1 型 RV DD(p = 0.17);7 名(27%)CPPD 和 OA 患者检测到 1 型 LV DD 和 RV DD。两组患者均未检测到 2 型和 3 型 DD。除 CRP 水平外(CPPD 患者的 CRP 水平更高)(P = 0.03),两组患者的心血管风险因素没有差异。在CPPD组中,左心室E/E'(p = 0.02)、LVDT(p = 0.03)和LVMI(p = 0.04)的平均值明显高于OA患者。相反,OA 患者的 EDV 指数(p = 0.004)和 TVC 指数(p = 0.02)更高。CPPD患者的舒张功能指数与下列因素有直接相关性:LVL、PWLV和PTH水平(r = 0.7,p = 0.05)。
{"title":"Diastolic Dysfunction of the Left and Right Ventricles in Patients with Calcium Pyrophosphate Crystal Storage Disease and Osteoarthritis","authors":"M. S. Eliseev,&nbsp;O. V. Zhelyabina,&nbsp;I. G. Kirillova,&nbsp;Yu. O. Korsakova,&nbsp;E. V. Cheremushkina","doi":"10.1134/S1607672924700881","DOIUrl":"10.1134/S1607672924700881","url":null,"abstract":"<p>The frequency and risk factors for the development of diastolic dysfunction (DD) in patients with CPPD and OA have not been studied. The objective of this study was to determine the frequency and identify risk factors (RF) for the development of DD of the left and right ventricles (LV and RV) in patients with calcium pyrophosphate crystal deposition disease (CPPD) and osteoarthritis (OA). The study included 26 patients with CPPD and with knee OA 18–65 years old, matched in age and gender, without cardiovascular disease (CVD), type 2 diabetes mellitus (DM2), and rheumatic diseases. Conventional risk factors (TRF) of CVD were assessed, and echocardiography was performed. The frequency of DD in patients with CPPD and OA was quite high and almost did not differ in both groups: it was detected in 19 patients, of which 11 (42%) had CPPD and 8 (31%) had OA (<i>p</i> = 0.39). Type 1 LV DD was detected in 10 (39%) patients with CPPD and in 8 (31%) with OA (<i>p</i> = 0.11); type 1RV DD was detected in 8 (31%) patients with CPPD and in 7 (27%) patients with OA (<i>p</i> = 0.17); and type 1 LV DD and RV DD was detected in 7 (27%) patients with both CPPD and with OA. DD types 2 and 3 were not detected in both groups. There were no differences in both groups in CV risk factors, except for the level of CRP (it was higher in CPPD) (<i>p</i> = 0.03). In the CPPD group, mean values of LV E/E' (<i>p</i> = 0.02), LVDT (<i>p</i> = 0.03), LVMI (<i>p</i> = 0.04) were significantly higher than in patients with OA. On the contrary, in patients with OA, indices EDV (<i>p</i> = 0.004) and TVC (<i>p</i> = 0.02) were higher. There were direct correlations between diastolic function indices and the following factors in CPPD: LVL, PWLV and PTH level (<i>r</i> = 0.7, <i>p</i> &lt;0.005), LV E' and PTH level (<i>r</i> = 0.7, <i>p</i> &lt; 0.005). Inverse correlations were found between the level of PTH and IS (<i>r</i> = –0.5, <i>p</i> &lt; 0.005), LVMI (<i>r</i> = –0.5, <i>p</i> &lt; 0.005), and the level of vitamin D and VDDT (<i>r</i> = –0.6, <i>p</i> &lt; 0.005). Direct correlations in OA were found between the level of CRP and PVAdiast (<i>r</i> = 0.6, <i>p</i> &lt; 0.005), and the level of sUA (<i>r</i> = 0.7, <i>p</i> &lt; 0.005), and the level of vitamin D and E/E'LV (<i>r</i> = 0.6, <i>p</i> &lt; 0.005). A high prevalence of LV and RV DD was found in patients with CPPD and OA. The presence of DD in CPPD was associated with lower vitamin D levels, and in OA with a higher level of sUA and a lower level of PTH.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"517 1","pages":"148 - 155"},"PeriodicalIF":0.8,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Schnitzler’s Syndrome—Diagnostic Experience, Approaches to Therapy, and Patient Management according to a Multicenter Russian Cohort 施尼茨勒综合征--诊断经验、治疗方法以及俄罗斯多中心队列的患者管理。
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-06-10 DOI: 10.1134/S1607672924700923
S. O. Salugina, A. V. Torgashina, E. Yu. Borzova, V. V. Rameev, V. R. Gorodetsky, E. S. Fedorov, N. V. Muravyova
<p>The objectives of the study were to present the experience of diagnosis, management, and therapy with IL-1 inhibitors in patients with Schnitzler’s syndrome (SchS) according to a multicenter Russian cohort. An observational retrospective study for a 10-year period (2012–2022) involved 17 patients with SchS who were admitted to the hospital or were observed on an outpatient basis (eight women and nine men). The diagnosis of all of them corresponded to the Strasbourg diagnostic criteria. The age of patients ranged from 25 to 81 years (Me 53[46; 56]). The age at the time of the onset of the disease ranged from 20 to 72 years (Me 46[39; 54]), the duration of the disease before diagnosis ranged from 1 to 35 years (Me 6.5[3; 6]), in three patients it exceeded 10 years, in the rest it ranged from 1 to 8 years. Infectious and lymphoproliferative diseases, monogenic AIDs (CAPS, TRAPS, and HIDS) were excluded from all patients at the prehospital stage. The referral diagnosis for all of them was Still 's disease in adults. Clinical manifestations of the disease in all patients included fatigue, lethargy, fatigue, rash, and fever. In all patients, skin elements were urticular and were accompanied by itching in 6 (37.5%) patients. Bone pain was observed in 12 (70.6%) patients; arthralgias, in 16 (94.1%); arthritis, in 9 (52.9%); myalgia, in 7 (41.2%); and weight loss, in 4 (23.5%). Lymphadenopathy was detected in 6 (35.3%) patients; enlarged liver, in 6 (35.3%); pericarditis, in 4 (23.5%); angioedema, in 6 (35.3); redness and dryness in the eyes, in 3 (17.6%); sore throat, in 2 (11.8%); abdominal pain, in 1 (5.9%), distal polyneuropathy, in 2 (11.8%); paraesthesia, in 1 (5.9%); and chondritis of the auricles, in 1 (5.9%). Monoclonal gammopathy was detected in all patients with a secretion level of 2.9–15.1 g/L: IgMk (<i>n</i> = 10, 64.7%), less often IgMλ (<i>n</i> = 2), IgGk (<i>n</i> = 2), IgGλ (<i>n</i> = 1), and IgAλ (<i>n</i> = 1). Ben-Jones protein was not detected in any of them. All patients had an increased level of ESR and CRP. Before inclusion in the study, 16 patients received GCs (94.1%) with a temporary effect that disappeared with dose reduction or cancellation. Seven patients received cDMARDs, including methotrexate (5), hydroxychloroquine (2), and cyclophosphamide (1). All patients received NSAIDs and antihistamines, as well as biologics, including the anti-B-cell drug rituximab (1), monoclonal ABs to IgE omalizumab (2, 1 without effect and 1 with partial effect), IL-1i canakinumab (<i>n</i> = 10, 58.8%) subcutaneously once every 8 weeks, and anakinra (<i>n</i> = 4, 23.5%) subcutaneously daily. The duration of taking anakinra, which was prescribed in the test mode, ranged from 1 week to 2.5 months with a further switch to canakinumab in 3 patients. The duration of taking canakinumab at the time of analysis ranged from 7 months to 8 years. Against the background of treatment with IL-1i, 10 out of 11 (90.9%) patients received a complete resp
该研究的目的是根据俄罗斯多中心队列,介绍施尼茨勒综合征(SchS)患者的诊断、管理和使用IL-1抑制剂治疗的经验。这项为期10年(2012-2022年)的观察性回顾研究涉及17名入院或门诊的施尼茨勒综合征患者(8名女性和9名男性)。所有患者的诊断均符合斯特拉斯堡诊断标准。患者的年龄从 25 岁到 81 岁不等(男性 53[46;56])。发病时的年龄从 20 岁到 72 岁不等(Me 46[39;54]),确诊前的病程从 1 年到 35 年不等(Me 6.5[3;6]),其中 3 名患者的病程超过 10 年,其余患者的病程从 1 年到 8 年不等。所有患者在入院前均排除了感染性疾病、淋巴增生性疾病、单基因艾滋病(CAPS、TRAPS 和 HIDS)。所有患者的转诊诊断均为成人斯蒂尔病。所有患者的临床表现包括乏力、嗜睡、疲倦、皮疹和发热。在所有患者中,有 6 人(37.5%)的皮肤呈荨麻疹状,并伴有瘙痒。12名患者(70.6%)出现骨痛;16名患者(94.1%)出现关节痛;9名患者(52.9%)出现关节炎;7名患者(41.2%)出现肌痛;4名患者(23.5%)体重减轻。6例(35.3%)患者出现淋巴结病;6例(35.3%)患者出现肝脏肿大;4例(23.5%)患者出现心包炎;6例(35.3%)患者出现血管性水肿;3例(17.6%)患者出现眼睛发红和干涩;3例(17.6%)患者出现喉咙痛。6%);喉咙痛,2 例(11.8%);腹痛,1 例(5.9%);远端多发性神经病,2 例(11.8%);麻痹,1 例(5.9%);耳廓软骨炎,1 例(5.9%)。在分泌水平为 2.9-15.1 克/升的所有患者中均检测到单克隆丙种球蛋白病:IgMk(10 例,64.7%),IgMλ(2 例)、IgGk(2 例)、IgGλ(1 例)和 IgAλ(1 例)较少见。所有患者均未检测到 Ben-Jones 蛋白。所有患者的血沉和 CRP 水平都有所升高。在纳入研究之前,16 名患者(94.1%)接受过 GCs 治疗,但效果暂时,剂量减少或取消后效果消失。7 名患者接受了 cDMARDs 治疗,包括甲氨蝶呤(5 例)、羟氯喹(2 例)和环磷酰胺(1 例)。所有患者都接受了非甾体抗炎药和抗组胺药以及生物制剂治疗,包括抗B细胞药物利妥昔单抗(1例)、IgE单克隆AB奥马珠单抗(2例,1例无效,1例部分有效)、IL-1i卡那珠单抗(10例,58.8%),每8周皮下注射1次,以及阿那金拉(4例,23.5%),每天皮下注射1次。以试验模式处方的 Anakinra 的服用时间从 1 周到 2.5 个月不等,有 3 名患者转为服用 canakinumab。在进行分析时,服用卡那单抗的时间从 7 个月到 8 年不等。在使用IL-1i治疗的背景下,11名患者中有10名(90.9%)在疾病的临床表现方面获得了完全应答,ESR和CRP水平在几天内有所下降。在一名患者中,检测到对服用 anakinra 有部分反应;然而,在改用 canakinumab 后,治疗效果最终消失。一名患者接受了8个月的IL-6i治疗,但疗效不完全,在改用anakinra后出现了积极的动态变化。因此,最初为四名患者开具了阿纳金拉处方,其中两名患者改用了卡纳库单抗;七名患者的第一种药物是卡纳库单抗。2 名患者继续使用阿纳金拉治疗,9 名患者继续使用卡那珠单抗治疗。在一名患者身上,由于一直没有复发,卡那单抗的注射间隔延长到了 5 个月,且没有再激活的迹象;但随后,在压力和疾病复发的背景下,注射间隔缩短到了 4 个月。同一患者在治疗期间生下了一个健康的孩子。所有患者对治疗的耐受性都很满意,未发现任何不良反应。SchS 是一种罕见的多因素/非单源性 AID,应与一些风湿性疾病和其他 AID 区分开来。成年后发病、出现反复发作的荨麻疹并伴有发热和其他全身炎症反应表现是检查单克隆分泌的指征。使用短效或长效 IL-1i 是治疗这类患者的一种高效、安全的选择。
{"title":"Schnitzler’s Syndrome—Diagnostic Experience, Approaches to Therapy, and Patient Management according to a Multicenter Russian Cohort","authors":"S. O. Salugina,&nbsp;A. V. Torgashina,&nbsp;E. Yu. Borzova,&nbsp;V. V. Rameev,&nbsp;V. R. Gorodetsky,&nbsp;E. S. Fedorov,&nbsp;N. V. Muravyova","doi":"10.1134/S1607672924700923","DOIUrl":"10.1134/S1607672924700923","url":null,"abstract":"&lt;p&gt;The objectives of the study were to present the experience of diagnosis, management, and therapy with IL-1 inhibitors in patients with Schnitzler’s syndrome (SchS) according to a multicenter Russian cohort. An observational retrospective study for a 10-year period (2012–2022) involved 17 patients with SchS who were admitted to the hospital or were observed on an outpatient basis (eight women and nine men). The diagnosis of all of them corresponded to the Strasbourg diagnostic criteria. The age of patients ranged from 25 to 81 years (Me 53[46; 56]). The age at the time of the onset of the disease ranged from 20 to 72 years (Me 46[39; 54]), the duration of the disease before diagnosis ranged from 1 to 35 years (Me 6.5[3; 6]), in three patients it exceeded 10 years, in the rest it ranged from 1 to 8 years. Infectious and lymphoproliferative diseases, monogenic AIDs (CAPS, TRAPS, and HIDS) were excluded from all patients at the prehospital stage. The referral diagnosis for all of them was Still 's disease in adults. Clinical manifestations of the disease in all patients included fatigue, lethargy, fatigue, rash, and fever. In all patients, skin elements were urticular and were accompanied by itching in 6 (37.5%) patients. Bone pain was observed in 12 (70.6%) patients; arthralgias, in 16 (94.1%); arthritis, in 9 (52.9%); myalgia, in 7 (41.2%); and weight loss, in 4 (23.5%). Lymphadenopathy was detected in 6 (35.3%) patients; enlarged liver, in 6 (35.3%); pericarditis, in 4 (23.5%); angioedema, in 6 (35.3); redness and dryness in the eyes, in 3 (17.6%); sore throat, in 2 (11.8%); abdominal pain, in 1 (5.9%), distal polyneuropathy, in 2 (11.8%); paraesthesia, in 1 (5.9%); and chondritis of the auricles, in 1 (5.9%). Monoclonal gammopathy was detected in all patients with a secretion level of 2.9–15.1 g/L: IgMk (&lt;i&gt;n&lt;/i&gt; = 10, 64.7%), less often IgMλ (&lt;i&gt;n&lt;/i&gt; = 2), IgGk (&lt;i&gt;n&lt;/i&gt; = 2), IgGλ (&lt;i&gt;n&lt;/i&gt; = 1), and IgAλ (&lt;i&gt;n&lt;/i&gt; = 1). Ben-Jones protein was not detected in any of them. All patients had an increased level of ESR and CRP. Before inclusion in the study, 16 patients received GCs (94.1%) with a temporary effect that disappeared with dose reduction or cancellation. Seven patients received cDMARDs, including methotrexate (5), hydroxychloroquine (2), and cyclophosphamide (1). All patients received NSAIDs and antihistamines, as well as biologics, including the anti-B-cell drug rituximab (1), monoclonal ABs to IgE omalizumab (2, 1 without effect and 1 with partial effect), IL-1i canakinumab (&lt;i&gt;n&lt;/i&gt; = 10, 58.8%) subcutaneously once every 8 weeks, and anakinra (&lt;i&gt;n&lt;/i&gt; = 4, 23.5%) subcutaneously daily. The duration of taking anakinra, which was prescribed in the test mode, ranged from 1 week to 2.5 months with a further switch to canakinumab in 3 patients. The duration of taking canakinumab at the time of analysis ranged from 7 months to 8 years. Against the background of treatment with IL-1i, 10 out of 11 (90.9%) patients received a complete resp","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"517 1","pages":"214 - 227"},"PeriodicalIF":0.8,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Significance of Antibodies to DFS70 in Immunoinflammatory Rheumatic Diseases 免疫炎症性风湿病中 DFS70 抗体的临床意义
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-06-10 DOI: 10.1134/S1607672924700911
T. A. Panafidina, Zh. G. Verizhnikova, A. S. Avdeeva, T. V. Popkova, E. L. Nasonov

The relevance of the problem of immunoinflammatory rheumatic diseases (IIRD) for modern medicine is determined by their high prevalence in the population, the difficulty of early diagnosis, the rapid development of disability and poor life prognosis. Recent data on the significance of anti-DFS70 have opened up new possibilities for optimizing the step-by-step diagnosis of IIRD. The detection of these antibodies can help in the interpretation of a positive result for antinuclear antibodies (ANA) by indirect immunofluorescence assay on HEp-2 cells (IIFA-HEp-2) in the absence of autoantibodies specific for IIRD. Detection of anti-DFS70 in antinuclear factor (ANF) seropositive patients without clinical and/or serological markers characteristic of a certain disease from the IIRD group can be considered as a potential marker that excludes this group of diseases.

免疫炎症性风湿病(IIRD)在人群中的高发病率、早期诊断的困难性、残疾的快速发展和不良的预后,决定了它与现代医学的相关性。最近关于抗DFS70重要性的数据为优化IIRD的逐步诊断提供了新的可能性。在没有 IIRD 特异性自身抗体的情况下,通过 HEp-2 细胞间接免疫荧光试验(IIFA-HEp-2)检测这些抗体有助于解释抗核抗体(ANA)阳性结果。在抗核因子(ANF)血清阳性患者中检测到抗DFS70,但没有IIRD组某种疾病的临床和/或血清学特征,可视为排除该组疾病的潜在标志物。
{"title":"Clinical Significance of Antibodies to DFS70 in Immunoinflammatory Rheumatic Diseases","authors":"T. A. Panafidina,&nbsp;Zh. G. Verizhnikova,&nbsp;A. S. Avdeeva,&nbsp;T. V. Popkova,&nbsp;E. L. Nasonov","doi":"10.1134/S1607672924700911","DOIUrl":"10.1134/S1607672924700911","url":null,"abstract":"<p>The relevance of the problem of immunoinflammatory rheumatic diseases (IIRD) for modern medicine is determined by their high prevalence in the population, the difficulty of early diagnosis, the rapid development of disability and poor life prognosis. Recent data on the significance of anti-DFS70 have opened up new possibilities for optimizing the step-by-step diagnosis of IIRD. The detection of these antibodies can help in the interpretation of a positive result for antinuclear antibodies (ANA) by indirect immunofluorescence assay on HEp-2 cells (IIFA-HEp-2) in the absence of autoantibodies specific for IIRD. Detection of anti-DFS70 in antinuclear factor (ANF) seropositive patients without clinical and/or serological markers characteristic of a certain disease from the IIRD group can be considered as a potential marker that excludes this group of diseases.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"517 1","pages":"207 - 213"},"PeriodicalIF":0.8,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Use of “Acellbia”—A Biosimilar of Rituximab in Systemic Sclerosis 在系统性硬化症中使用 "Acellbia"--一种利妥昔单抗的生物仿制药。
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-06-10 DOI: 10.1134/S1607672924700844
L. P. Ananyeva, L. A. Garzanova, O. V. Desinova, R. U. Shayakhmetova, M. N. Starovoitova, O. A. Koneva, O. B. Ovsyannikova, S. I. Glukhova, E. L. Nasonov

The possibilities of modern therapy for systemic sclerosis (SSc) remains limited, since most of the used drugs do not have a disease-modifying effect. This encourages the study of new approaches that potentially affect the fundamental pathological processes underlying the disease. One example is anti-B-cell therapy, in particular rituximab (RTX). Until now RTX does not have a registration for the treatment of SSc, but there is a large positive experience of its use, which is reflected in recent meta-analyses and clinical recommendations. Complicated and expensive methods for obtaining genetically engineered biological drugs (biologics) have contributed to the emergence of more accessible biosimilars, one of which is the RTX biosimilar, Acellbia (Biocad, Russian Federation). The ‘‘biosimilar’’ versions of RTX might reduce the cost of therapy and increase patients accessibility to this treatment option. The RTX biosimilar Acellbia (ACB) has received approval in Russian Federation in 2014 for all indications held by reference RTX (including rheumatoid arthritis and ANCA-associated vasculitis).

现代疗法治疗系统性硬化症(SSc)的可能性仍然有限,因为大多数常用药物都没有改变病情的作用。这就促使人们研究有可能影响疾病基本病理过程的新方法。其中一个例子就是抗 B 细胞疗法,特别是利妥昔单抗(RTX)。到目前为止,利妥昔单抗还没有注册用于治疗 SSc,但使用该疗法已有大量积极的经验,这反映在最近的荟萃分析和临床建议中。获得基因工程生物药物(生物制剂)的方法复杂而昂贵,这促使出现了更容易获得的生物仿制药,RTX 生物仿制药 Acellbia(俄罗斯联邦 Biocad 公司)就是其中之一。RTX的 "生物仿制药 "可能会降低治疗成本,使患者更容易获得这种治疗选择。RTX生物仿制药Acellbia(ACB)已于2014年在俄罗斯联邦获得批准,可用于参考RTX的所有适应症(包括类风湿性关节炎和ANCA相关性血管炎)。
{"title":"The Use of “Acellbia”—A Biosimilar of Rituximab in Systemic Sclerosis","authors":"L. P. Ananyeva,&nbsp;L. A. Garzanova,&nbsp;O. V. Desinova,&nbsp;R. U. Shayakhmetova,&nbsp;M. N. Starovoitova,&nbsp;O. A. Koneva,&nbsp;O. B. Ovsyannikova,&nbsp;S. I. Glukhova,&nbsp;E. L. Nasonov","doi":"10.1134/S1607672924700844","DOIUrl":"10.1134/S1607672924700844","url":null,"abstract":"<p>The possibilities of modern therapy for systemic sclerosis (SSc) remains limited, since most of the used drugs do not have a disease-modifying effect. This encourages the study of new approaches that potentially affect the fundamental pathological processes underlying the disease. One example is anti-B-cell therapy, in particular rituximab (RTX). Until now RTX does not have a registration for the treatment of SSc, but there is a large positive experience of its use, which is reflected in recent meta-analyses and clinical recommendations. Complicated and expensive methods for obtaining genetically engineered biological drugs (biologics) have contributed to the emergence of more accessible biosimilars, one of which is the RTX biosimilar, Acellbia (Biocad, Russian Federation). The ‘‘biosimilar’’ versions of RTX might reduce the cost of therapy and increase patients accessibility to this treatment option. The RTX biosimilar Acellbia (ACB) has received approval in Russian Federation in 2014 for all indications held by reference RTX (including rheumatoid arthritis and ANCA-associated vasculitis).</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"517 1","pages":"140 - 147"},"PeriodicalIF":0.8,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Olokizumab against Comorbid Depressive Disorder in Patients with Rheumatoid Arthritis: Preliminary Results of the Study Olokizumab对类风湿性关节炎患者合并抑郁障碍的疗效:研究的初步结果。
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-06-10 DOI: 10.1134/S160767292470090X
T. A. Lisitsyna, A. A. Abramkin, D. Yu. Veltishchev, O. F. Seravina, O. B. Kovalevskaya, A. B. Borisova, V. G. Ignatiev, E. L. Nasonov
<p>Interleukin (IL) 6 plays an important role in the pathogenesis of depression comorbid with rheumatoid arthritis (RA), and IL-6 inhibitors used to treat patients with RA may have an antidepressant effect. The objective of the study was to evaluate the effectiveness of Russian iIL-6 olokizumab (OKZ) in reducing symptoms of depression in patients with moderate/high RA activity. To date, 49 RA patients have been included, of which 43 (87.7%) are women, with an average age of 47.8 ± 12.8 years; with a predominant high activity of RA according to DAS28 (CRP) indices (89.8%), SDAI (79.6%) and CDAI (75.5%) and inefficacy of stable 12-week therapy with сDMARDs. In all patients, a psychiatrist, in accordance with ICD-10, diagnosed depression (chronic or recurrent) of varying severity during a semi-structured interview. At week 0, all patients were randomized by the method of sequential numbers in a ratio of 1 : 1 : 1 to one of the three study groups: group 1—cDMARDs + OKZ 64 mg subcutaneously once every 4 weeks (<i>n</i> = 18); group 2—cDMARDs + OKZ 64 mg subcutaneously once every 4 weeks + psychopharmacotherapy (PPT) (<i>n</i> = 26); group 3—cDMARDs + PPT (<i>n</i> = 5). The duration of the study is 24 weeks. The dynamics of depression severity was assessed on the PHQ-9, MADRS scales; anxiety, on HAM-A; experimental psychological projective techniques were also used. After 12 and 24 weeks of therapy, there was a significant decrease in the severity of depression and anxiety in all groups of patients. However, the difference between the final and initial values of all scales was statistically significantly greater (<i>p</i> <0.05) in the groups of patients receiving PPT: cDMARDs + OKZ + PPT (Δ<sub>PHQ-9 24–0</sub> = –6.75 ± 3.91; Δ<sub>MADRS 24–0</sub> = –22.5 ± 4.83; Δ<sub>HAM-A 24-0</sub> = –14.6 ± 5.37) and cDMARDs + PPT (Δ<sub>PHQ-9 24–0</sub> = –15.5 ± 3.53; Δ<sub>MADRS 24–0</sub> = –25.0 ± 1.41; Δ<sub>HAM-A 24-0</sub> = –18.5 ± 3.53), compared with the cDMARDs + OKZ group (Δ<sub>PHQ-9 24–0</sub> = –4.00 ± 3.89; Δ<sub>MADRS 24-0</sub> = –5.75 ± 8.29; Δ<sub>HAM-A 24–0</sub> = –8.50 ± 8.21). According to a semi-structured interview with a psychiatrist and design experimental psychological techniques, the proportion of patients without depression after 24 weeks of therapy was significantly higher in the groups of patients receiving PPT: 90% in the group of cDMARDs + OKZ + PPT and 100%—cDMARDs + PPT, as opposed to 25% in the group of cDMARDs + OKZ. OKZ therapy contributed to the normalization of night sleep but did not lead to a decrease in the frequency and severity of cognitive disorders (CDs). OKZ has an antidepressant effect, leads to a decrease in the frequency of sleep disorders. However, a complete regression of depression symptoms when OKZ is prescribed without PPT is possible only in 25% of RA patients, mainly in the patients with mild depression. A combination of OKZ and PPT is optimal for the complete regression of depression and anxiety
白细胞介素(IL)6在类风湿关节炎(RA)合并抑郁症的发病机制中起着重要作用,用于治疗RA患者的IL-6抑制剂可能具有抗抑郁作用。该研究旨在评估俄罗斯 iIL-6 olokizumab(OKZ)在减轻中度/高度 RA 活动患者抑郁症状方面的效果。迄今为止,该研究共纳入了49名RA患者,其中43名(87.7%)为女性,平均年龄为(47.8 ± 12.8)岁;根据DAS28(CRP)指数(89.8%)、SDAI(79.6%)和CDAI(75.5%),RA患者以高活动性为主,且使用сDMARDs进行为期12周的稳定治疗无效。在半结构化访谈中,精神科医生根据 ICD-10 诊断了所有患者不同严重程度的抑郁症(慢性或复发性)。在第0周,所有患者按1 : 1 : 1的比例随机分配到三个研究组中的一组:第1组-CDMARDs + OKZ 64 mg皮下注射,每4周1次(n = 18);第2组-CDMARDs + OKZ 64 mg皮下注射,每4周1次 + 精神药物疗法(PPT)(n = 26);第3组-CDMARDs + PPT(n = 5)。研究持续时间为 24 周。抑郁严重程度的动态评估采用 PHQ-9、MADRS 量表;焦虑采用 HAM-A;还采用了实验性心理投射技术。经过 12 周和 24 周的治疗后,各组患者的抑郁和焦虑严重程度均有显著下降。然而,所有量表的最终值与初始值之间的差异在统计学上明显更大(P PHQ-9 24-0 = -6.75 ± 3.91;ΔMADRS 24-0 = -22.5 ± 4.83;ΔHAM-A 24-0 = -14.6 ± 5.37)。37)和 cDMARDs + PPT(ΔPHQ-9 24-0 = -15.5 ± 3.53;ΔMADRS 24-0 = -25.0 ± 1.41;ΔHAM-A 24-0 = -18.5 ± 3.53),而 cDMARDs + OKZ 组(ΔPHQ-9 24-0 = -4.00 ± 3.89;ΔMADRS 24-0 = -5.75 ± 8.29;ΔHAM-A 24-0 = -8.50 ± 8.21)。根据与精神科医生进行的半结构化访谈和设计的实验心理技术,接受 PPT 治疗的患者在治疗 24 周后无抑郁的比例明显更高:cDMARDs + OKZ + PPT 组为 90%,cDMARDs + PPT 组为 100%,而 cDMARDs + OKZ 组为 25%。OKZ疗法有助于夜间睡眠正常化,但并没有降低认知障碍(CD)的频率和严重程度。OKZ具有抗抑郁作用,可降低睡眠障碍的发生频率。然而,在不使用 PPT 的情况下使用 OKZ,只有 25% 的 RA 患者(主要是轻度抑郁症患者)的抑郁症状可以完全缓解。OKZ 和 PPT 的最佳组合是完全缓解抑郁和焦虑,降低 CD 的频率和严重程度。
{"title":"Efficacy of Olokizumab against Comorbid Depressive Disorder in Patients with Rheumatoid Arthritis: Preliminary Results of the Study","authors":"T. A. Lisitsyna,&nbsp;A. A. Abramkin,&nbsp;D. Yu. Veltishchev,&nbsp;O. F. Seravina,&nbsp;O. B. Kovalevskaya,&nbsp;A. B. Borisova,&nbsp;V. G. Ignatiev,&nbsp;E. L. Nasonov","doi":"10.1134/S160767292470090X","DOIUrl":"10.1134/S160767292470090X","url":null,"abstract":"&lt;p&gt;Interleukin (IL) 6 plays an important role in the pathogenesis of depression comorbid with rheumatoid arthritis (RA), and IL-6 inhibitors used to treat patients with RA may have an antidepressant effect. The objective of the study was to evaluate the effectiveness of Russian iIL-6 olokizumab (OKZ) in reducing symptoms of depression in patients with moderate/high RA activity. To date, 49 RA patients have been included, of which 43 (87.7%) are women, with an average age of 47.8 ± 12.8 years; with a predominant high activity of RA according to DAS28 (CRP) indices (89.8%), SDAI (79.6%) and CDAI (75.5%) and inefficacy of stable 12-week therapy with сDMARDs. In all patients, a psychiatrist, in accordance with ICD-10, diagnosed depression (chronic or recurrent) of varying severity during a semi-structured interview. At week 0, all patients were randomized by the method of sequential numbers in a ratio of 1 : 1 : 1 to one of the three study groups: group 1—cDMARDs + OKZ 64 mg subcutaneously once every 4 weeks (&lt;i&gt;n&lt;/i&gt; = 18); group 2—cDMARDs + OKZ 64 mg subcutaneously once every 4 weeks + psychopharmacotherapy (PPT) (&lt;i&gt;n&lt;/i&gt; = 26); group 3—cDMARDs + PPT (&lt;i&gt;n&lt;/i&gt; = 5). The duration of the study is 24 weeks. The dynamics of depression severity was assessed on the PHQ-9, MADRS scales; anxiety, on HAM-A; experimental psychological projective techniques were also used. After 12 and 24 weeks of therapy, there was a significant decrease in the severity of depression and anxiety in all groups of patients. However, the difference between the final and initial values of all scales was statistically significantly greater (&lt;i&gt;p&lt;/i&gt; &lt;0.05) in the groups of patients receiving PPT: cDMARDs + OKZ + PPT (Δ&lt;sub&gt;PHQ-9 24–0&lt;/sub&gt; = –6.75 ± 3.91; Δ&lt;sub&gt;MADRS 24–0&lt;/sub&gt; = –22.5 ± 4.83; Δ&lt;sub&gt;HAM-A 24-0&lt;/sub&gt; = –14.6 ± 5.37) and cDMARDs + PPT (Δ&lt;sub&gt;PHQ-9 24–0&lt;/sub&gt; = –15.5 ± 3.53; Δ&lt;sub&gt;MADRS 24–0&lt;/sub&gt; = –25.0 ± 1.41; Δ&lt;sub&gt;HAM-A 24-0&lt;/sub&gt; = –18.5 ± 3.53), compared with the cDMARDs + OKZ group (Δ&lt;sub&gt;PHQ-9 24–0&lt;/sub&gt; = –4.00 ± 3.89; Δ&lt;sub&gt;MADRS 24-0&lt;/sub&gt; = –5.75 ± 8.29; Δ&lt;sub&gt;HAM-A 24–0&lt;/sub&gt; = –8.50 ± 8.21). According to a semi-structured interview with a psychiatrist and design experimental psychological techniques, the proportion of patients without depression after 24 weeks of therapy was significantly higher in the groups of patients receiving PPT: 90% in the group of cDMARDs + OKZ + PPT and 100%—cDMARDs + PPT, as opposed to 25% in the group of cDMARDs + OKZ. OKZ therapy contributed to the normalization of night sleep but did not lead to a decrease in the frequency and severity of cognitive disorders (CDs). OKZ has an antidepressant effect, leads to a decrease in the frequency of sleep disorders. However, a complete regression of depression symptoms when OKZ is prescribed without PPT is possible only in 25% of RA patients, mainly in the patients with mild depression. A combination of OKZ and PPT is optimal for the complete regression of depression and anxiety ","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"517 1","pages":"195 - 206"},"PeriodicalIF":0.8,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Binary Proton Therapy of Ehrlich Carcinoma Using Targeted Gold Nanoparticles 利用靶向金纳米粒子对艾氏癌进行双质子治疗
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-05-25 DOI: 10.1134/S1607672924700819
M. V. Filimonova, D. D. Kolmanovich, G. V. Tikhonowski, D. S. Petrunya, P. A. Kotelnikova, A. A. Shitova, O. V. Soldatova, A. S. Filimonov, V. A. Rybachuk, A. O. Kosachenko, K. A. Nikolaev, G. A. Demyashkin, A. A. Popov, M. S. Savinov, A. L. Popov, I. V. Zelepukin, A. A. Lipengolts, K. E. Shpakova, A. V. Kabashin, S. N. Koryakin,  S. M. Deyev, I. N. Zavestovskaya

Proton therapy can treat tumors located in radiation-sensitive tissues. This article demonstrates the possibility of enhancing the proton therapy with targeted gold nanoparticles that selectively recognize tumor cells. Au-PEG nanoparticles at concentrations above 25 mg/L and 4 Gy proton dose caused complete death of EMT6/P cells in vitro. Binary proton therapy using targeted Au-PEG-FA nanoparticles caused an 80% tumor growth inhibition effect in vivo. The use of targeted gold nanoparticles is promising for enhancing the proton irradiation effect on tumor cells and requires further research to increase the therapeutic index of the approach.

质子疗法可以治疗位于辐射敏感组织中的肿瘤。本文展示了利用能选择性识别肿瘤细胞的靶向金纳米粒子增强质子疗法的可能性。浓度高于 25 mg/L 的 Au-PEG 纳米粒子和 4 Gy 质子剂量在体外可导致 EMT6/P 细胞完全死亡。使用靶向 Au-PEG-FA 纳米粒子的二元质子疗法在体内可抑制 80% 的肿瘤生长。靶向金纳米粒子的使用有望增强质子辐照对肿瘤细胞的作用,需要进一步研究以提高该方法的治疗指数。
{"title":"Binary Proton Therapy of Ehrlich Carcinoma Using Targeted Gold Nanoparticles","authors":"M. V. Filimonova,&nbsp;D. D. Kolmanovich,&nbsp;G. V. Tikhonowski,&nbsp;D. S. Petrunya,&nbsp;P. A. Kotelnikova,&nbsp;A. A. Shitova,&nbsp;O. V. Soldatova,&nbsp;A. S. Filimonov,&nbsp;V. A. Rybachuk,&nbsp;A. O. Kosachenko,&nbsp;K. A. Nikolaev,&nbsp;G. A. Demyashkin,&nbsp;A. A. Popov,&nbsp;M. S. Savinov,&nbsp;A. L. Popov,&nbsp;I. V. Zelepukin,&nbsp;A. A. Lipengolts,&nbsp;K. E. Shpakova,&nbsp;A. V. Kabashin,&nbsp;S. N. Koryakin,&nbsp; S. M. Deyev,&nbsp;I. N. Zavestovskaya","doi":"10.1134/S1607672924700819","DOIUrl":"10.1134/S1607672924700819","url":null,"abstract":"<p>Proton therapy can treat tumors located in radiation-sensitive tissues. This article demonstrates the possibility of enhancing the proton therapy with targeted gold nanoparticles that selectively recognize tumor cells. Au-PEG nanoparticles at concentrations above 25 mg/L and 4 Gy proton dose caused complete death of EMT6/P cells in vitro. Binary proton therapy using targeted Au-PEG-FA nanoparticles caused an 80% tumor growth inhibition effect in vivo. The use of targeted gold nanoparticles is promising for enhancing the proton irradiation effect on tumor cells and requires further research to increase the therapeutic index of the approach.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"516 1","pages":"111 - 114"},"PeriodicalIF":0.8,"publicationDate":"2024-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141097188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Frequency-Dependent Variability of Pulse Wave Transit Time: Pilot Study 脉搏波传输时间随频率的变化:试验性研究
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-05-25 DOI: 10.1134/S1607672924700807
A. A. Grinevich, N. K. Chemeris

The dynamics of the pulse wave (PW) associated with the PW transit time variability (PWTTV) determines the peripheral pulse rate variability, which is used as a surrogate for heart rate variability (HRV). The aim of the work is to analyze the frequency-dependent dynamics of PWTTV and to identify the possible frequency-phase modulation of PW velocity oscillations on the transit from the heart to the soft tissues of the distal parts of the upper extremities. RR-interval recordings and synchronous records of photoplethysmograms of 12 conditionally healthy subjects from the PhysioNet open database were used in this work. Using the Hilbert–Huang transform 3 spectral components of PWTTV and HRV were identified. It was shown that the amplitudes of PWTTV oscillations were many times (up to 8.4 times) smaller than the amplitudes of HRV, and the peaks of PWTTV spectral components were shifted towards higher frequencies than those of HRV. Functional relations between PWTTV and HRV, which can determine the phase modulation of periodic changes in the PW propagation velocity, were revealed.

脉搏波(PW)的动态变化与脉搏波传输时间变异性(PWTTV)有关,它决定了外周脉率变异性,而外周脉率变异性被用作心率变异性(HRV)的代用指标。这项工作的目的是分析脉搏波传输时间变异的频率动态,并确定脉搏波速度振荡从心脏传输到上肢远端软组织时可能存在的频率相位调制。这项研究使用了物理网开放数据库中 12 名条件健康受试者的 RR 间隔记录和光速图同步记录。利用希尔伯特-黄变换识别了 PWTTV 和 HRV 的 3 个频谱成分。结果表明,脉搏波色谱图振荡的振幅比心率变异的振幅小很多倍(最多为 8.4 倍),而且脉搏波色谱图频谱成分的峰值比心率变异的峰值偏向于更高的频率。研究揭示了 PWTTV 与心率变异之间的功能关系,这种关系可以确定 PW 传播速度周期性变化的相位调制。
{"title":"Frequency-Dependent Variability of Pulse Wave Transit Time: Pilot Study","authors":"A. A. Grinevich,&nbsp;N. K. Chemeris","doi":"10.1134/S1607672924700807","DOIUrl":"10.1134/S1607672924700807","url":null,"abstract":"<p>The dynamics of the pulse wave (PW) associated with the PW transit time variability (PWTTV) determines the peripheral pulse rate variability, which is used as a surrogate for heart rate variability (HRV). The aim of the work is to analyze the frequency-dependent dynamics of PWTTV and to identify the possible frequency-phase modulation of PW velocity oscillations on the transit from the heart to the soft tissues of the distal parts of the upper extremities. RR-interval recordings and synchronous records of photoplethysmograms of 12 conditionally healthy subjects from the PhysioNet open database were used in this work. Using the Hilbert–Huang transform 3 spectral components of PWTTV and HRV were identified. It was shown that the amplitudes of PWTTV oscillations were many times (up to 8.4 times) smaller than the amplitudes of HRV, and the peaks of PWTTV spectral components were shifted towards higher frequencies than those of HRV. Functional relations between PWTTV and HRV, which can determine the phase modulation of periodic changes in the PW propagation velocity, were revealed.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"516 1","pages":"107 - 110"},"PeriodicalIF":0.8,"publicationDate":"2024-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141097202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Doklady Biochemistry and Biophysics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1